Drug Profile
Droxidopa - Sumitomo Pharma/Lundbeck
Alternative Names: 3,4-Dihydroxyphenylserine; 3,4-threo-DOPS; Dops; L-DOPS; L-threo-dihydroxyphenylserine; L-threodops; Northera; Threo-dopaserine; Threo-DOPSLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Dainippon Sumitomo Pharma
- Developer Chelsea Therapeutics; Lundbeck A/S; Sumitomo Pharma
- Class Amino acids; Antiparkinsonians; Catecholamines; Small molecules
- Mechanism of Action Adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Amyloid polyneuropathy; Dizziness; Intradialytic hypotension; Orthostatic hypotension
- Discontinued Attention-deficit hyperactivity disorder; Chronic fatigue syndrome; Fibromyalgia
Most Recent Events
- 01 Apr 2022 Sumitomo Dainippon Pharma is now called Sumitomo Pharma
- 14 Feb 2022 Lundbeck withdrew phase II trial prior to enrolment due to sponsored decision in Fatigue (Parkinsonism) (PO) (NCT03446807)
- 03 Sep 2021 Discontinued - Phase-II for Intradialytic hypotension in USA (PO) (Lundbeck website, September 2021)